Search
Displaying 271–280 of 624 for “retinal diseases”
-
Resource
Dr. Jacque Duncan, UCSF Professor of Clinical Ophthalmology, is currently working on therapies restoring vision for retinal degenerative diseases. Dr. Duncan has hope and optimism for the future that vision will be restored for those with retinal diseases, thanks in part by the Foundation’s work.
-
ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study
Research NewsFrancois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
-
Unregulated Stem-Cell Therapy Causes Severe Vision Loss for Three Florida Women
Research News“…participation in a study for an emerging therapy that is not regulated by the FDA or another well-recognized regulatory agency like the European Medicines Agency in Europe, is fraught with dangers and can lead to unexpected serious consequences.”
-
Past Sun Exposure Increases AMD Risk
Research NewsResearchers from the University of Cologne in Germany and Radboud University in the Netherlands found that increased sunlight exposure during working life significantly increases risk of AMD later in life.
-
Just How Tricky Halloween Can Be
Beacon StoriesFor those with night blindness, a symptom of many retinal diseases, most notably retinitis pigmentosa, or RP, navigating a trick-or-treating throng can be, well, a nightmare.
-
The FDA's Indispensible Role (a guest blog from Dr. Patricia Zilliox)
Research NewsWhile it may not seem obvious, the FDA ultimately drives everything — the researchers and the money. That’s because without FDA approval, you have no treatment, even if you have great research and adequate funding.
-
Beacon Stories
The parents of young children affected by retinal diseases walk a fine line – between making the best of a trying situation and preparing for the worst.
-
Foundation Fighting Blindness Comments on Proposed NIH Reforms
Foundation NewsThe Foundation responds to the U.S. House of Representatives Energy and Commerce Committee on the framework for reforming the National Institutes of Health
-
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
Research NewsThe AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
